Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Nurix Therapeutics, Inc. (NRIX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 71,000,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 14,534 54,131 165,162 205,587
Total Sell Value $184,556 $1,038,138 $3,511,297 $3,893,612
Total People Sold 3 3 3 3
Total Sell Transactions 4 13 33 48
End Date 2025-02-01 2024-10-31 2024-05-02 2023-05-03

   
Records found: 233
  Page 1 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-04-30 4 S $11.50 $38,841 D/D (3,377) 61,516     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-04-30 4 OE $0.00 $0 D/D 8,956 64,893     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-04-30 4 S $11.50 $28,041 D/D (2,438) 39,922     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-04-30 4 OE $0.00 $0 D/D 8,636 42,360     -
   Ring Christine Chief Legal Officer   •       –      –    2025-04-30 4 S $11.50 $33,286 D/D (2,894) 37,318     -
   Ring Christine Chief Legal Officer   •       –      –    2025-04-30 4 OE $0.00 $0 D/D 7,674 40,212     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-03-03 4 AS $14.40 $84,388 D/D (5,825) 33,724     -
   Ring Christine Chief Legal Officer   •       –      –    2025-01-31 4 AS $19.94 $114,934 D/D (5,760) 32,538     -
   Ring Christine Chief Legal Officer   •       –      –    2025-01-31 4 OE $1.86 $10,714 D/D 5,760 38,298     -
   Ring Christine Chief Legal Officer   •       –      –    2025-01-30 4 S $19.81 $63,929 D/D (3,220) 32,538     -
   Ring Christine Chief Legal Officer   •       –      –    2025-01-30 4 OE $0.00 $0 D/D 7,674 35,758     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-01-30 4 S $19.81 $73,260 D/D (3,690) 55,937     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-01-30 4 OE $0.00 $0 D/D 8,957 59,627     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-01-30 4 S $19.81 $55,809 D/D (2,811) 39,549     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-01-30 4 OE $0.00 $0 D/D 8,636 42,360     -
   Ring Christine Chief Legal Officer   •       –      –    2025-01-02 4 AS $19.50 $112,295 D/D (5,760) 28,084     -
   Ring Christine Chief Legal Officer   •       –      –    2025-01-02 4 OE $1.86 $10,714 D/D 5,760 33,844     -
   Ring Christine Chief Legal Officer   •       –      –    2024-12-02 4 AS $21.73 $125,155 D/D (5,760) 28,084     -
   Ring Christine Chief Legal Officer   •       –      –    2024-12-02 4 OE $1.86 $10,714 D/D 5,760 33,844     -
   Ring Christine Chief Legal Officer   •       –      –    2024-11-04 4 AS $25.00 $82,250 D/D (3,290) 28,084     -
   Ring Christine Chief Legal Officer   •       –      –    2024-11-04 4 OE $9.57 $31,485 D/D 3,290 31,374     -
   Ring Christine Chief Legal Officer   •       –      –    2024-11-01 4 AS $24.28 $139,867 D/D (5,760) 28,084     -
   Ring Christine Chief Legal Officer   •       –      –    2024-11-01 4 OE $1.86 $10,714 D/D 5,760 33,844     -
   Van Houte Hans Chief Financial Officer   •       –      –    2024-11-01 4 AS $24.28 $86,083 D/D (3,546) 33,724     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2024-10-30 4 S $24.31 $83,536 D/D (3,437) 50,670     -
  233 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us